PRIME designation granted by European Medicines Agency for Roche ’s risdiplam for treatment of spinal muscular atrophy (SMA)

Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational oral medicine risdiplam (RG7916) for the treatment of people with SMA.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news